# Hon Hai (2317.TW): Solid 1022 revenues growth while 2022 to be affected by COVID and soft market demand; Neutral

Hon Hai 1Q22 revenues were solid at +5% YoY, despite the Shenzhen factory site lockdown for around a week, in our view demonstrating the company's strong execution and bargaining power with the supply chain. However, with more regional lockdowns in 2Q22 in China, especially in Shanghai, Kunshan, and Zhengzhou, along with soft consumer electronics market demand, we expect revenue growth in 2Q22 to be lower than 1Q22, at +0% YoY. Although Hon Hai's mega sites production is operating normally under COVID, we expect the logistics and supply chain disruption could still weight on its revenue growth. Note that we continue to expect revenue growth to be better than 1Q20 (-12% YoY) during the initial COVID outbreak in China with a nationwide impact. We believe Hon Hai's strong execution and experience in 2020 could better offset the COVID impact in 2Q22 compared to 2020.

**Earnings revision:** We factor in 1Q22 revenues and thus lift 2022-23E revenues by 5% / 1%. We also newly introduced 2024E estimates, we continue to expect modest revenue growth ahead through 2024E with +0% / -4% / -3% YoY in 2022-24E, considering growing competition in EMS, while its automotive business remains small (0.6% / 1.0% / 1.4% of 2022-24E revenues). We lower our GM estimate to reflect the concerns on growing competition and additional costs due to COVID, and now expect GM to stay at 2021 level of 6.0% in 2022-24E supported by improving costs control, and better product mix (more exposure from CSP, components, and automotive). With a lower GM, our EPS estimates are down by 5% / 1% for 2022 / 23E.

Verena Jeng +852-2978-1681 | verena.jeng@gs.com Goldman Sachs (Asia) L.L.C.

Allen Chang +852-2978-2930 | allen.k.chang@gs.com Goldman Sachs (Asia) L.L.C.

Yuhe Wu +852-2978-1072 | yuhe.wu@gs.com Goldman Sachs (Asia) L.L.C.

Goldman Sachs does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. For Reg AC certification and other important disclosures, see the Disclosure Appendix, or go to <u>www.gs.com/research/hedge.html</u>. Analysts employed by non-US affiliates are not registered/qualified as research analysts with FINRA in the U.S.

		2022E	2023E			
NT m	Old	New	Chg	Old	New	Chg
Revenues	5,735,305	6,008,778	5%	5,723,997	5,781,336	1%
GP	365,935	359,428	-2%	373,592	362,148	-3%
OP	156,733	148,658	-5%	170,464	163,984	-4%
Net income	145,587	139,493	-4%	147,250	147,127	0%
EPS	10.35	9.84	-5%	10.46	10.38	-1%
Margins						
GM	6.4%	6.0%		6.5%	6.3%	
OPM	2.7%	2.5%		3.0%	2.8%	
NM	2.5%	2.3%		2.6%	2.5%	

#### Exhibit 1: Earnings revisions

Source: Goldman Sachs Global Investment Research

**Valuation:** We continue to use PE methodology to derive target price and roll over to 2023 from 2022. With forward year earnings growth largely unchanged at 1% YoY, we keep our target PE multiple unchanged at 11x, which is in line with the company's historical trading average. Our 12-month target price is thus unchanged at NT\$114 (11x 2023E PE). Maintain Neutral.

**Upside risks:** Better-than-expected outlook for iPhone shipments; lower-than-expected opex ratio caused by a further increase in automated production, or further cost control on SG&A.

**Downside risks:** A strong USD against RMB/TWD is a key downside risk given Apple is its main customer, contributing to 40-50% of revenues based on our estimates. Hon Hai's factories are located mainly in mainland China, with costs based in Rmb.

# Exhibit 2: Hon Hai financials summary

Hon Hai (2317.TW)	2019	2020	2021	2022E	2023E	2024
NTD bn P&L						
Revenue	5.343	5.358	5.994	6.009	5.781	5.60
COGS	(5,027)	(5,055)	(5,632)	(5,649)	(5,419)	(5,252
Gross profit	316	303	362	359	362	354
Operating expense	(201)	(192)	(213)	(211)	(198)	(18
EBITDA	182	176	224	230	248	25
D&A	(67)	(65)	(75)	(81)	(84)	(8
EBIT	115	111	149	149	164	16
Net interest income/(expense)			10	2	2	
Disposal of assets (pre-tax)	1	(0)	4	0	0	
Others	39	27	30	27	21	1
Pretax profit	164	145	194	178	187	18
Income tax	(32)	(31)	(40)	(38)	(40)	(4
Minorities	(17)	(13)	(15)	(00)	0	(.
Net income pre-preferred dividends	115	102	139	139	147	14
Preferred dividends	0	0			0	
Net income (pre-exceptionals)	115	102	139	139	147	14
Post-tax exceptionals	0	0	105	0		
Net income	115	102	139	139	147	14
	115	102	100	100	14/	
EPS (NTD)	8.2	7.3	9.9	9.8	10.4	10
DPS (NTD)	4.2	4.0	4.0	4.0	4.0	4
Dividend payout ratio	50%	54%	40%	41%	39%	38
Growth & margins						
Revenue growth	0.9%	0.3%	11.9%	0.2%	-3.8%	-3.0
EBITDA growth	-7.2%	-3.3%	27.6%	2.3%	8.2%	1.8
EBIT growth	-15.6%	-3.5%	34.4%	-0.2%	10.3%	1.6
Net income growth	-10.7%	-11.7%	36.9%	0.1%	5.5%	0.5
EPS growth	2.4%	-11.6%	36.4%	-0.7%	5.5%	0.5
Gross margin	5.9%	5.7%	6.0%	6.0%	6.3%	6.3
EBITDA margin	3.4%	3.3%	3.7%	3.8%	4.3%	4.5
EBIT margin	2.2%	2.1%	2.5%	2.5%	2.8%	3.0
2011 margin	2.270	2.170	2.070	2.070	2.070	0.0
NTD bn	2Q21	3Q21	4Q21	1Q22E	2Q22E	3Q22
Quarterly						
Revenue	1,351.5	1,405.8	1,889.8	1,408.2	1,353.9	1,395
EBIT	32.5	36.2	52.7	32.1	25.7	39
EBIT margin	2.4%	2.6%	2.8%	2.3%	1.9%	2.8
Pretax profit	44.2	47.9	62.2	39.3	33.0	46
Net income	29.8	37.0	44.4	30.9	25.9	36

Hon Ha	(2317.TW)

	2019	2020	2021	2022E	2023E	2024
NTD bn						
Cash flow statement						
Net income	115	102	139	139	147	148
D&A add-back	67	65	75	81	84	86
Minorities add-back	17	13	15	0	0	9
Net(inc)/dec working capital	93	182	(298)	14	(27)	9
Other operating cash flow	(44)	16	(29)	0	0	(
Cash flow from operations	248	378	(98)	235	204	24
Capital expenditures	(78)	(66)	(92)	(93)	(89)	(8
Acquisitions)/divestitures	28	11	(5)	0	0	
Others	120	89	6	0	0	
Cash flow from investments	71	35	(92)	(93)	(89)	(8
Dividend paid (common & pref)	(55)	(58)	(55)	(56)	(57)	(5
nc/(dec) in debt	(109)	86	124	0	Ó	
Share repurchase/issue (change In common	0	0	0	0	0	
Other financing cash flows	(53)	(53)	(44)	0	0	
Cash flow from financing	(218)	(25)	24	(56)	(57)	(5
Total cash flow	101	387	(166)	86	58	10
Free cash flow	170	312	(191)	142	115	15
NTD bn	2019	2020	2021	2022E	2023E	2024
	2019	2020	2021	2022E	2023E	2024
Balance sheet	2019 858	2020	2021	2022E	2023E 1,204	
Balance sheet Cash & equivalent						1,30
Balance sheet Cash & equivalent Net receivables	858	1,233	1,059	1,146	1,204	1,30
Balance sheet Cash & equivalent Vet receivables nventory	858 1,032	1,233 942	1,059	1,146 1,144	1,204 1,201	1,30 1,16 70
Balance sheet Cash & equivalent Vet receivables Inventory Other current asset	858 1,032 516	1,233 942 582	1,059 1,161 672	1,146 1,144 659	1,204 1,201 707	1,30 1,16 70 79
Salance sheet Cash & equivalent det receivables nventory Dher current asset Total current assets Vet PP&E	858 1,032 516 629 <b>2,574</b> 288	1,233 942 582 714 <b>2,885</b> 287	1,059 1,161 672 788 <b>3,034</b> 310	1,146 1,144 659 789 <b>3,090</b> 327	1,204 1,201 707 790 <b>3,253</b> 336	1,30 1,10 70 <b>3,3</b> ° 34
Balance sheet Cash & equivalent Vet receivables Inventory Other current asset Total current assets Vet IPP&E Vet Intangibles	858 1,032 516 629 <b>2,574</b> 288 41	1,233 942 582 714 <b>2,885</b> 287 47	1,059 1,161 672 788 <b>3,034</b> 310 45	1,146 1,144 659 789 <b>3,090</b> 327 40	1,204 1,201 707 790 <b>3,253</b> 336 36	1,30 1,10 70 <b>3,3</b> 34
Balance sheet Cash & equivalent Vet receivables Inventory Other current asset Total current assets Net PP&E Net intangibles Total investments	858 1,032 516 629 <b>2,574</b> 288 41 337	1,233 942 582 714 <b>2,885</b> 287 47 175	1,059 1,161 672 788 <b>3,034</b> 310 45 195	1,146 1,144 659 789 <b>3,090</b> 327 40 195	1,204 1,201 707 790 <b>3,253</b> 336 36 195	1,3( 1,1( 7( <b>3,3</b> 3, 3, 1(
Salance sheet Cash & equivalent Vet receivables nventory Dher current asset Fotal current assets Vet IP8& Vet intangibles Fotal investments Dher long-term assets	858 1,032 516 629 <b>2,574</b> 288 41 337 81	1,233 942 582 714 <b>2,885</b> 287 47 175 280	1,059 1,161 672 788 <b>3,034</b> 310 45 195 324	1,146 1,144 659 <b>789</b> <b>3,090</b> 327 40 195 324	1,204 1,201 707 <b>3,253</b> 336 36 195 324	1,3( 1,1( 7( <b>3,3</b> 3, 3, 3, 1( 3, 3, 3, 1) 3, 3, 1)
Salance sheet Cash & equivalent Vet receivables nventory Dher current asset Fotal current assets Vet IP8& Vet intangibles Fotal investments Dher long-term assets	858 1,032 516 629 <b>2,574</b> 288 41 337	1,233 942 582 714 <b>2,885</b> 287 47 175	1,059 1,161 672 788 <b>3,034</b> 310 45 195	1,146 1,144 659 789 <b>3,090</b> 327 40 195	1,204 1,201 707 790 <b>3,253</b> 336 36 195	1,3( 1,1( 7( <b>3,3</b> 3, 3, 3, 1( 3, 3, 3, 1) 3, 3, 1)
Balance sheet Cash & equivalent Vet receivables Inventory Other current asset Total current assets Net Intangibles Total investments Other long-term assets Total assets	858 1,032 516 629 <b>2,574</b> 288 41 337 81	1,233 942 582 714 <b>2,885</b> 287 47 175 280	1,059 1,161 672 788 <b>3,034</b> 310 45 195 324	1,146 1,144 659 <b>789</b> <b>3,090</b> 327 40 195 324	1,204 1,201 707 <b>3,253</b> 336 36 195 324	1,3( 1,1( 7( <b>3,3</b> ) 3( 3) 3( 3) 4,2(
Balance sheet Cash & equivalent Vet receivables Inventory Other current asset Total current assets Net Intangibles Total investments Other long-term assets Total assets Account payables Short-term debt	858 1,032 516 629 <b>2,574</b> 288 41 337 81 <b>3,321</b> 906 434	1,233 942 582 714 <b>2,885</b> 287 47 175 280 <b>3,674</b> 1,066 503	1,059 1,161 672 788 <b>3,034</b> 310 45 195 324 <b>3,909</b> 1,076 585	1,146 1,144 659 789 <b>3,090</b> 327 40 195 324 <b>3,976</b> 1,060 585	1,204 1,201 707 790 <b>3,253</b> 336 195 324 <b>4,144</b> 1,138 585	1,30 1,16 70 3,31 34 32 32 4,20 1,10 58
Jalance sheet           Cash & equivalent           Vet receivables           nventory           Dither current asset           Fotal current assets           Vet Intangibles           Total investments           Dither long-term assets           Fotal assets           Account payables           Short-term debt           Dither current liabilities	858 1,032 516 629 <b>2,574</b> 288 41 337 81 <b>3,321</b> 906 434 317	1,233 942 582 714 <b>2,885</b> 287 47 175 280 <b>3,674</b> 1,066 503 347	1,059 1,161 672 788 <b>3,034</b> 310 45 195 324 <b>3,909</b> 1,076 585 337	1,146 1,144 659 789 <b>3,090</b> 327 40 195 324 <b>3,976</b> 1,060 585 337	1,204 1,201 707 790 <b>3,253</b> 336 36 195 324 <b>4,144</b> 1,138 585 337	1,30 1,16 70 3,31 34 32 4,20 1,10 58 33
Salance sheet Dash & equivalent ket receivables nventory Dher current asset Total current assets vet intangibles Total investments Dither long-term assets Total assets Account payables Short-term debt Dher current liabilities Total current liabilities	858 1,032 516 629 <b>2,574</b> 285 41 337 81 <b>3,321</b> 906 434 317 <b>1,657</b>	1,233 942 582 714 <b>2,885</b> 287 47 175 280 <b>3,674</b> 1,066 503 347 <b>1,916</b>	1,059 1,161 672 788 <b>3,034</b> 310 45 195 324 <b>3,909</b> 1,076 585 337 <b>1,998</b>	1,146 1,144 659 789 <b>3,090</b> 327 40 195 324 <b>3,976</b> 1,060 585 337 <b>1,982</b>	1,204 1,201 707 790 <b>3,253</b> 336 195 324 <b>4,144</b> 1,138 585 337 <b>2,060</b>	1,30 1,16 70 3,31 34 32 4,20 1,10 58 33 2,02
Balance sheet Cash & equivalent Vet receivables Inventory Other current asset Total current assets Net Intangibles Total Investments Dither Iong-term assets Total assets Account payables Short-term debt Dither current liabilities Total current liabilities Cong-term debt	858 1,032 516 629 <b>2,574</b> 288 41 337 81 <b>3,321</b> 906 434 317 <b>1,657</b> 217	1,233 942 582 714 <b>2,885</b> 287 47 175 280 <b>3,674</b> 1,066 503 347 <b>1,916</b> 233	1,059 1,161 672 788 <b>3,034</b> 310 45 195 324 <b>3,909</b> 1,076 585 337 <b>1,998</b> 276	1,146 1,144 659 789 3,090 327 40 195 324 3,976 1,060 585 337 1,982 276	1,204 1,201 707 3,253 336 36 195 324 4,144 1,138 585 337 2,060 276	1,30 1,16 70 3,31 32 4,20 1,10 58 33 2,02 21
Balance sheet Cash & equivalent Vet receivables niventory Other current asset Total current assets Vet IPAE Vet Intanjbles Total investments Other tong-term assets Total assets Account payables Short-term debt Other current liabilities Code current tiabilities Long-term debt Dither cong-term dabt	858 1,032 516 629 2,574 288 41 3,321 906 434 317 1,657 217 47	1,233 942 582 714 <b>2,885</b> 287 47 175 280 <b>3,674</b> 1,066 503 347 <b>1,916</b> 233 51	1,059 1,161 672 788 <b>3,034</b> 310 45 195 324 <b>3,909</b> 1,076 585 337 <b>1,998</b> 276 62	1,146 1,144 659 789 3,090 327 40 195 324 3,976 1,060 585 337 1,982 276 62	1,204 1,201 707 3,253 336 36 195 324 4,144 1,138 585 337 2,060 276 62	1,30 1,10 70 3,3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Balance sheet Cash & equivalent Vet receivables niventory Other current asset Total current assets Vet IPAE Vet Intanjbles Total investments Other tong-term assets Total assets Account payables Short-term debt Other current liabilities Code current tiabilities Long-term debt Dither cong-term dabt	858 1,032 516 629 <b>2,574</b> 288 41 337 81 <b>3,321</b> 906 434 317 <b>1,657</b> 217	1,233 942 582 714 <b>2,885</b> 287 47 175 280 <b>3,674</b> 1,066 503 347 <b>1,916</b> 233	1,059 1,161 672 788 <b>3,034</b> 310 45 195 324 <b>3,909</b> 1,076 585 337 <b>1,998</b> 276	1,146 1,144 659 789 3,090 327 40 195 324 3,976 1,060 585 337 1,982 276	1,204 1,201 707 3,253 336 36 195 324 4,144 1,138 585 337 2,060 276	1,30 1,10 70 3,3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Balance sheet Cash & equivalent Vet receivables Inventory Other current asset Total current assets Vet PP&E Vet Intangibles Total investments Other long-term assets Short-term debt Other current liabilities Total long-term liabilities Total long-term liabilities	858 1,032 516 629 2,574 288 41 3,321 906 434 317 1,657 217 47	1,233 942 582 714 <b>2,885</b> 287 47 175 280 <b>3,674</b> 1,066 503 347 <b>1,916</b> 233 51	1,059 1,161 672 788 <b>3,034</b> 310 45 195 324 <b>3,909</b> 1,076 585 337 <b>1,998</b> 276 62	1,146 1,144 659 789 3,090 327 40 195 324 3,976 1,060 585 337 1,982 276 62	1,204 1,201 707 3,253 336 36 195 324 4,144 1,138 585 337 2,060 276 62	2024 1,30 1,30 70 75 3,31 32 4,20 1,10 58 33 2,00 2,36 2,36
Balance sheet Cash & equivalent Vet receivables Inventory Other current asset Total current assets Net PP&E Net intangibles Total investments Other long-term assets Total assets Account payables Short-term debt Other current liabilities Total current liabilities Total current liabilities Total Iabilities	858 858 1,032 516 629 2,574 288 41 337 81 3,321 906 434 317 1,657 217 47 264	1,233 942 582 714 2,885 287 47 175 280 <b>3,674</b> 1,066 503 347 <b>1,916</b> 233 51 284	1,059 1,161 672 788 3,034 310 45 195 324 3,909 1,076 585 337 1,998 276 62 338	1,146 1,144 659 789 3,090 3,090 3,27 40 195 324 3,976 1,060 585 337 1,982 2,76 62 2,338	1,204 1,201 707 3,253 336 36 195 324 4,144 1,138 585 337 2,060 276 62 338	1,30 1,16 70 3,31 34 32 4,20 1,10 58 33 2,02 27 6 33
NTD bn Balance sheet Cash & equivalent Vet receivables Inventory Other current assets Total current assets Total current assets Total investments Other long-term assets Total assets Account payables Short-term debt Other current liabilities Total current liabilities Total current liabilities Total liabilities Total liabilities Total component liabilities Total com	858 1,032 516 629 <b>2,574</b> 288 41 337 81 <b>3,321</b> 906 434 317 <b>1,657</b> 217 47 264 <b>1,921</b>	1,233 942 582 714 <b>2,885</b> 287 47 175 280 <b>3,674</b> 1,066 503 347 <b>1,916</b> 233 51 284 <b>2,200</b>	1,059 1,161 672 788 3,034 310 45 195 324 3,909 1,076 585 337 1,998 276 62 338 2,336	1,146 1,144 659 7699 3,090 327 40 195 324 3,976 1,060 585 337 1,982 276 62 338 2,320	1,204 1,201 707 3,253 3,36 3,6 195 3,24 4,144 1,138 5,85 3,37 2,060 2,766 2,338 2,398	1,30 1,16 75 3,31 32 32 4,20 1,10 58 33 2,02 27 6 33 2,02 2,02 2,02 2,03 33 2,36

Source: Company data, Goldman Sachs Global Investment Research

2317.TW	12m Price	Price: NT\$	102.00	Upside: <b>11.8%</b>		
Neutral		GS Forecast				
			12/21	12/22E	12/23E	12/24E
Market cap: NT\$1.	4tr / \$48.0bn	Revenue (NT\$ mn) New	5,994,173.9	6,008,778.1	5,781,335.9	5,605,847.5
Ente	erprise value:	Revenue (NT\$ mn) Old	5,961,967.6	5,735,305.3	5,723,997.2	-
NT\$1.	3tr / \$44.8bn	EBITDA (NT\$ mn)	224,440.7	229,559.4	248,396.1	252,802.2
3m ADTV: NT\$2.7		EPS (NT\$) New	9.90	9.84	10.38	10.4
	Taiwan	EPS (NT\$) Old	10.14	10.50	10.62	
Greater China	a Technology V&A Bank: 3	P/E (X)	11.3	10.4	9.8	9.8
Leases incl. in net		P/B (X)	1.1	1.0	0.9	0.9
Leases Inci. In het	No	Dividend yield (%)	3.6	3.9	3.9	3.9
	110	CROCI (%)	13.5	13.3	13.2	12.5
			12/21	3/22E	6/22E	9/22
		EPS (NT\$)	3.13	2.18	1.83	2.5

Source: Company data, Goldman Sachs Research estimates, FactSet. Price as of 29 Apr 2022 close.

# **Disclosure Appendix**

# **Reg AC**

We, Verena Jeng, Allen Chang and Yuhe Wu, hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Unless otherwise stated, the individuals listed on the cover page of this report are analysts in Goldman Sachs' Global Investment Research division.

# **GS Factor Profile**

The Goldman Sachs Factor Profile provides investment context for a stock by comparing key attributes to the market (i.e. our coverage universe) and its sector peers. The four key attributes depicted are: Growth, Financial Returns, Multiple (e.g. valuation) and Integrated (a composite of Growth, Financial Returns and Multiple). Growth, Financial Returns and Multiple are calculated by using normalized ranks for specific metrics for each stock. The normalized ranks for the metrics are then averaged and converted into percentiles for the relevant attribute. The precise calculation of each metric may vary depending on the fiscal year, industry and region, but the standard approach is as follows:

**Growth** is based on a stock's forward-looking sales growth, EBITDA growth and EPS growth (for financial stocks, only EPS and sales growth), with a higher percentile indicating a higher growth company. **Financial Returns** is based on a stock's forward-looking ROE, ROCE and CROCI (for financial stocks, only ROE), with a higher percentile indicating a company with higher financial returns. **Multiple** is based on a stock's forward-looking P/E, P/B, price/dividend (P/D), EV/EBITDA, EV/FCF and EV/Debt Adjusted Cash Flow (DACF) (for financial stocks, only P/E, P/B and P/D), with a higher percentile indicating a stock trading at a higher multiple. The **Integrated** percentile is calculated as the average of the Growth percentile, Financial Returns percentile.

Financial Returns and Multiple use the Goldman Sachs analyst forecasts at the fiscal year-end at least three quarters in the future. Growth uses inputs for the fiscal year at least seven quarters in the future compared with the year at least three quarters in the future (on a per-share basis for all metrics).

For a more detailed description of how we calculate the GS Factor Profile, please contact your GS representative.

# **M&A Rank**

Across our global coverage, we examine stocks using an M&A framework, considering both qualitative factors and quantitative factors (which may vary across sectors and regions) to incorporate the potential that certain companies could be acquired. We then assign a M&A rank as a means of scoring companies under our rated coverage from 1 to 3, with 1 representing high (30%-50%) probability of the company becoming an acquisition target, 2 representing medium (15%-30%) probability and 3 representing low (0%-15%) probability. For companies ranked 1 or 2, in line with our standard departmental guidelines we incorporate an M&A component into our target price. M&A rank of 3 is considered immaterial and therefore does not factor into our price target, and may or may not be discussed in research.

# Quantum

Quantum is Goldman Sachs' proprietary database providing access to detailed financial statement histories, forecasts and ratios. It can be used for in-depth analysis of a single company, or to make comparisons between companies in different sectors and markets.

# **Disclosures**

The rating(s) for Hon Hai is/are relative to the other companies in its/their coverage universe: 3PEAK, AAC, ACM Research, AMEC, ASMPT, AccoTest, Actions Technology, Amlogic, Anji Micro, Anlogic, Arcsoft, Awinic, BOE, Bestechnic, CFME, CR Micro, China Mobile (HK), China Telecom (H), China Tower Corp., China Unicom (H), China United Network Comm, Chinasoft Intl, Chipown, Comba, Dahua, Desay SV, Espressif, Etek, FIT Hon Teng, Fiberhome, Foxconn Industrial Internet, GalaxyCore, Gigadevice, Goodix, Hengtong, Hikvision, Hon Hai, Hua Hong, JCET, Jingce, Kingdee, Kingsemi, Kingsoft Office, Largan, Lenovo, Luxshare, Maxscend, Montage, NAURA, NSIG, NavInfo Co., O-film, Primarius, Rockchip, Ruijie, SG Micro, SMIC, Sanan, Sangfor, Shennan Circuits, Silan, SinoWealth, StarPower, Sunny Optical, Thundersoft, Thunisoft, Tuya, USI, Venustech, VeriSilicon, Weimob, Will Semi, Wingtech, YJK, YOFC (A), YOFC (H), Yonyou, ZTE (A), ZTE (H), ZWSOFT, iFlytek

# **Company-specific regulatory disclosures**

The following disclosures relate to relationships between The Goldman Sachs Group, Inc. (with its affiliates, "Goldman Sachs") and companies covered by the Global Investment Research Division of Goldman Sachs and referred to in this research.

Goldman Sachs has received compensation for investment banking services in the past 12 months: Hon Hai (NT\$102.00)

Goldman Sachs expects to receive or intends to seek compensation for investment banking services in the next 3 months: Hon Hai (NT\$102.00)

Goldman Sachs has received compensation for non-investment banking services during the past 12 months: Hon Hai (NT\$102.00)

Goldman Sachs had an investment banking services client relationship during the past 12 months with: Hon Hai (NT\$102.00)

Goldman Sachs had a non-investment banking securities-related services client relationship during the past 12 months with: Hon Hai (NT\$102.00)


Goldman Sachs had a non-securities services client relationship during the past 12 months with: Hon Hai (NT\$102.00)

#### Distribution of ratings/investment banking relationships Goldman Sachs Investment Research global Equity coverage universe

	F	Rating Distribution	n		Investme	ent Banking Relat	tionships
	Buy	Hold	Sell	-	Buy	Hold	Sell
Global	50%	35%	15%		65%	57%	45%

As of April 1, 2022, Goldman Sachs Global Investment Research had investment ratings on 3,143 equity securities. Goldman Sachs assigns stocks as Buys and Sells on various regional Investment Lists; stocks not so assigned are deemed Neutral. Such assignments equate to Buy, Hold and Sell for the purposes of the above disclosure required by the FINRA Rules. See 'Ratings, Coverage universe and related definitions' below. The Investment Banking Relationships chart reflects the percentage of subject companies within each rating category for whom Goldman Sachs has provided investment banking services within the previous twelve months.

## Price target and rating history chart(s)



The price targets shown should be considered in the context of all prior published Goldman. Sachs research, which may or may not have included price targets, as well as developments relating to the company, its industry and financial markets.

# **Regulatory disclosures**

# **Disclosures required by United States laws and regulations**

See company-specific regulatory disclosures above for any of the following disclosures required as to companies referred to in this report: manager or co-manager in a pending transaction; 1% or other ownership; compensation for certain services; types of client relationships; managed/co-managed public offerings in prior periods; directorships; for equity securities, market making and/or specialist role. Goldman Sachs trades or may trade as a principal in debt securities (or in related derivatives) of issuers discussed in this report.

The following are additional required disclosures: **Ownership and material conflicts of interest:** Goldman Sachs policy prohibits its analysts, professionals reporting to analysts and members of their households from owning securities of any company in the analyst's area of coverage. **Analyst compensation:** Analysts are paid in part based on the profitability of Goldman Sachs, which includes investment banking revenues. **Analyst as officer or director:** Goldman Sachs policy generally prohibits its analysts, persons reporting to analysts or members of their households from serving as an officer, director or advisor of any company in the analyst's area of coverage. **Non-U.S. Analysts**: Non-U.S. analysts may not be associated persons of Goldman Sachs & Co. LLC and therefore may not be subject to FINRA Rule 2241 or FINRA Rule 2242 restrictions on communications with subject company, public appearances and trading securities held by the analysts.

**Distribution of ratings:** See the distribution of ratings disclosure above. **Price chart:** See the price chart, with changes of ratings and price targets in prior periods, above, or, if electronic format or if with respect to multiple companies which are the subject of this report, on the Goldman Sachs website at <a href="https://www.gs.com/research/hedge.html">https://www.gs.com/research/hedge.html</a>.

# Additional disclosures required under the laws and regulations of jurisdictions other than the United States

The following disclosures are those required by the jurisdiction indicated, except to the extent already made above pursuant to United States laws and regulations. Australia: Goldman Sachs Australia Pty Ltd and its affiliates are not authorised deposit-taking institutions (as that term is defined in the Banking Act 1959 (Cth)) in Australia and do not provide banking services, nor carry on a banking business, in Australia. This research, and any access to it, is intended only for "wholesale clients" within the meaning of the Australian Corporations Act, unless otherwise agreed by Goldman Sachs. In producing research reports, members of the Global Investment Research Division of Goldman Sachs Australia may attend site visits and other meetings hosted by the companies and other entities which are the subject of its research reports. In some instances the costs of such site visits or meetings may be met in part or in whole by the issuers concerned if Goldman Sachs Australia considers it is appropriate and reasonable in the specific circumstances relating to the site visit or meeting. To the extent that the contents of this document contains any financial product advice, it is general advice only and has been prepared by Goldman Sachs without taking into account a client's objectives, financial situation or needs. A client should, before acting on any such advice, consider the appropriateness of the advice having regard to the client's own objectives, financial situation and needs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests and a copy of Goldman Sachs' Australian Sell-Side Research Independence Policy Statement are available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. Brazil: Disclosure information in relation to CVM Resolution n. 20 is available at https://www.gs.com/worldwide/brazil/area/gir/index.html. Where applicable, the Brazil-registered analyst primarily responsible for the content of this research report, as defined in Article 20 of CVM Resolution n. 20, is the first author named at the beginning of this report, unless indicated otherwise at the end of the text. Canada: This information is being provided to you for information purposes only and is not, and under no circumstances should be construed as, an advertisement, offering or solicitation by Goldman Sachs & Co. LLC for purchasers of securities in Canada to trade in any Canadian security. Goldman Sachs & Co. LLC is not registered as a dealer in any jurisdiction in Canada under applicable Canadian securities laws and generally is not permitted to trade in Canadian securities and may be prohibited from selling certain securities and products in certain jurisdictions in Canada. If you wish to trade in any Canadian securities or other products in Canada please contact Goldman Sachs Canada Inc., an affiliate of The Goldman Sachs Group Inc., or another registered Canadian dealer. Hong Kong: Further information on the securities of covered companies referred to in this research may be obtained on request from Goldman Sachs (Asia) L.L.C. India: Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (India) Securities Private Limited, Research Analyst - SEBI Registration Number INH000001493, 951-A, Rational House, Appasaheb Marathe Marg, Prabhadevi, Mumbai 400 025, India, Corporate Identity Number U74140MH2006FTC160634, Phone +91 22 6616 9000, Fax +91 22 6616 9001. Goldman Sachs may beneficially own 1% or more of the securities (as such term is defined in clause 2 (h) the Indian Securities Contracts (Regulation) Act, 1956) of the subject company or companies referred to in this research report. Japan: See below. Korea: This research, and any access to it, is intended only for "professional investors" within the meaning of the Financial Services and Capital Markets Act, unless otherwise agreed by Goldman Sachs. Further information on the subject company or companies referred to in this research may be obtained from Goldman Sachs (Asia) L.L.C., Seoul Branch. New Zealand: Goldman Sachs New Zealand Limited and its affiliates are neither "registered banks" nor "deposit takers" (as defined in the Reserve Bank of New Zealand Act 1989) in New Zealand. This research, and any access to it, is intended for "wholesale clients" (as defined in the Financial Advisers Act 2008) unless otherwise agreed by Goldman Sachs. A copy of certain Goldman Sachs Australia and New Zealand disclosure of interests is available at: https://www.goldmansachs.com/disclosures/australia-new-zealand/index.html. Russia: Research reports distributed in the Russian Federation are not

advertising as defined in the Russian legislation, but are information and analysis not having product promotion as their main purpose and do not provide appraisal within the meaning of the Russian legislation on appraisal activity. Research reports do not constitute a personalized investment recommendation as defined in Russian laws and regulations, are not addressed to a specific client, and are prepared without analyzing the financial circumstances, investment profiles or risk profiles of clients. Goldman Sachs assumes no responsibility for any investment decisions that may be taken by a client or any other person based on this research report. **Singapore:** Goldman Sachs (Singapore) Pte. (Company Number: 198602165W), which is regulated by the Monetary Authority of Singapore, accepts legal responsibility for this research, and should be contacted with respect to any matters arising from, or in connection with, this research. **Taiwan:** This material is for reference only and must not be reprinted without permission. Investors should carefully consider their own investment risk. Investment results are the responsibility of the individual investor. **United Kingdom:** Persons who would be categorized as retail clients in the United Kingdom, as such term is defined in the rules of the Financial Conduct Authority, should read this research in conjunction with prior Goldman Sachs research on the covered companies referred to herein and should refer to the risk warnings that have been sent to them by Goldman Sachs International. A copy of these risks warnings, and a glossary of certain financial terms used in this report, are available from Goldman Sachs International on request.

**European Union and United Kingdom:** Disclosure information in relation to Article 6 (2) of the European Commission Delegated Regulation (EU) (2016/958) supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council (including as that Delegated Regulation is implemented into United Kingdom domestic law and regulation following the United Kingdom's departure from the European Union and the European Economic Area) with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest is available at <u>https://www.gs.com/disclosures/europeanpolicy.html</u> which states the European Policy for Managing Conflicts of Interest in Connection with Investment Research.

Japan: Goldman Sachs Japan Co., Ltd. is a Financial Instrument Dealer registered with the Kanto Financial Bureau under registration number Kinsho 69, and a member of Japan Securities Dealers Association, Financial Futures Association of Japan and Type II Financial Instruments Firms Association. Sales and purchase of equities are subject to commission pre-determined with clients plus consumption tax. See company-specific disclosures as to any applicable disclosures required by Japanese stock exchanges, the Japanese Securities Dealers Association or the Japanese Securities Finance Company.

## Ratings, coverage universe and related definitions

Buy (B), Neutral (N), Sell (S) Analysts recommend stocks as Buys or Sells for inclusion on various regional Investment Lists. Being assigned a Buy or Sell on an Investment List is determined by a stock's total return potential relative to its coverage universe. Any stock not assigned as a Buy or a Sell on an Investment List with an active rating (i.e., a stock that is not Rating Suspended, Not Rated, Coverage Suspended or Not Covered), is deemed Neutral. Each region's Investment Review Committee manages Regional Conviction lists, which represent investment recommendations focused on the size of the total return potential and/or the likelihood of the realization of the return across their respective areas of coverage. The addition or removal of stocks from such Conviction lists do not represent a change in the analysts' investment rating for such stocks.

**Total return potential** represents the upside or downside differential between the current share price and the price target, including all paid or anticipated dividends, expected during the time horizon associated with the price target. Price targets are required for all covered stocks. The total return potential, price target and associated time horizon are stated in each report adding or reiterating an Investment List membership.

Coverage Universe: A list of all stocks in each coverage universe is available by primary analyst, stock and coverage universe at https://www.gs.com/research/hedge.html.

Not Rated (NR). The investment rating, target price and earnings estimates (where relevant) have been suspended pursuant to Goldman Sachs policy when Goldman Sachs is acting in an advisory capacity in a merger or in a strategic transaction involving this company, when there are legal, regulatory or policy constraints due to Goldman Sachs' involvement in a transaction, and in certain other circumstances. Rating Suspended (RS). Goldman Sachs Research has suspended the investment rating and price target for this stock, because there is not a sufficient fundamental basis for determining an investment rating or target price. The previous investment rating and target price, if any, are no longer in effect for this stock and should not be relied upon. Coverage Suspended (CS). Goldman Sachs has suspended coverage of this company. Not Covered (NC). Goldman Sachs does not cover this company. Not Available or Not Applicable (NA). The information is not available for display or is not applicable. Not Meaningful (NM). The information is not available for display or is not applicable.

# **Global product; distributing entities**

The Global Investment Research Division of Goldman Sachs produces and distributes research products for clients of Goldman Sachs on a global basis. Analysts based in Goldman Sachs offices around the world produce research on industries and companies, and research on macroeconomics, currencies, commodities and portfolio strategy. This research is disseminated in Australia by Goldman Sachs Australia Pty Ltd (ABN 21 006 797 897); in Brazil by Goldman Sachs do Brasil Corretora de Títulos e Valores Mobiliários S.A.; Public Communication Channel Goldman Sachs Brazil: 0800 727 5764 and / or contatogoldmanbrasil@gs.com. Available Weekdays (except holidays), from 9am to 6pm. Canal de Comunicação com o Público Goldman Sachs Brasil: 0800 727 5764 e/ou contatogoldmanbrasil@gs.com. Horário de funcionamento: segunda-feira à sexta-feira (exceto feriados), das 9h à 18h; in Canada by Goldman Sachs & Co. LLC; in Hong Kong by Goldman Sachs (Asia) L.L.C.; in India by Goldman Sachs (India) Securities Private Ltd.; in Japan by Goldman Sachs Japan Co., Ltd.; in the Republic of Korea by Goldman Sachs (Asia) L.L.C., Seoul Branch; in New Zealand by Goldman Sachs New Zealand Limited; in Russia by OOO Goldman Sachs; in Singapore by Goldman Sachs (Singapore) Pte. (Company Number: 198602165W); and in the United States of America by Goldman Sachs & Co. LLC. Goldman Sachs International has approved this research in connection with its distribution in the United Kingdom.

Effective from the date of the United Kingdom's departure from the European Union and the European Economic Area ("Brexit Day") the following information with respect to distributing entities will apply:

Goldman Sachs International ("GSI"), authorised by the Prudential Regulation Authority ("PRA") and regulated by the Financial Conduct Authority ("FCA") and the PRA, has approved this research in connection with its distribution in the United Kingdom.

**European Economic Area:** GSI, authorised by the PRA and regulated by the FCA and the PRA, disseminates research in the following jurisdictions within the European Economic Area: the Grand Duchy of Luxembourg, Italy, the Kingdom of Belgium, the Kingdom of Denmark, the Kingdom of Norway, the Republic of Finland, the Republic of Cyprus and the Republic of Ireland; GS -Succursale de Paris (Paris branch) which, from Brexit Day, will be authorised by the French Autorité de contrôle prudentiel et de resolution ("ACPR") and regulated by the Autorité de contrôle prudentiel et de resolution ("ACPR") and regulated by the Autorité de contrôle prudentiel et de resolution ("ACPR") and regulated by the Autorité de contrôle prudentiel et de resolution spain by the Comisión Nacional del Mercado de Valores disseminates research in France; GSI - Sucursal en España (Madrid branch) authorized in Spain by the SFSA as a "third country branch" in accordance with Chapter 4, Section 4 of the Swedish Securities and Market Act (Sw. lag (2007:528) om värdepappersmarknaden) disseminates research in the Kingdom of Sweden; Goldman Sachs Bank Europe SE ("GSBE") is a credit institution incorporated in Germany and, within the Single Supervisory Mechanism, subject to direct prudential supervision by the European Central Bank and in other respects supervised by German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and Deutsche Bundesbank and disseminates research in the Federal Republic of Germany and hose jurisdictions within the European Cenomic Area where GSI is not authorised to disseminate research and additionally, GSBE, Copenhagen Branch filial af GSBE, Tyskland, supervised by the Danish

Financial Authority disseminates research in the Kingdom of Denmark; GSBE - Sucursal en España (Madrid branch) subject (to a limited extent) to local supervision by the Bank of Spain disseminates research in the Kingdom of Spain; GSBE - Sucursale Italia (Milan branch) to the relevant applicable extent, subject to local supervision by the Bank of Italy (Banca d'Italia) and the Italian Companies and Exchange Commission (Commissione Nazionale per le Società e la Borsa "Consob") disseminates research in Italy; GSBE - Sucursale de Paris (Paris branch), supervised by the AMF and by the ACPR disseminates research in France; and GSBE - Sweden Bankfilial (Stockholm branch), to a limited extent, subject to local supervision by the Swedish Financial Supervisory Authority (Finansinpektionen) disseminates research in the Kingdom of Sweden.

#### **General disclosures**

This research is for our clients only. Other than disclosures relating to Goldman Sachs, this research is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. The information, opinions, estimates and forecasts contained herein are as of the date hereof and are subject to change without prior notification. We seek to update our research as appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as appropriate in the analyst's judgment.

Goldman Sachs conducts a global full-service, integrated investment banking, investment management, and brokerage business. We have investment banking and other business relationships with a substantial percentage of the companies covered by our Global Investment Research Division. Goldman Sachs & Co. LLC, the United States broker dealer, is a member of SIPC (<u>https://www.sipc.org</u>).

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients and principal trading desks that reflect opinions that are contrary to the opinions expressed in this research. Our asset management area, principal trading desks and investing businesses may make investment decisions that are inconsistent with the recommendations or views expressed in this research.

The analysts named in this report may have from time to time discussed with our clients, including Goldman Sachs salespersons and traders, or may discuss in this report, trading strategies that reference catalysts or events that may have a near-term impact on the market price of the equity securities discussed in this report, which impact may be directionally counter to the analyst's published price target expectations for such stocks. Any such trading strategies are distinct from and do not affect the analyst's fundamental equity rating for such stocks, which rating reflects a stock's return potential relative to its coverage universe as described herein.

We and our affiliates, officers, directors, and employees, excluding equity and credit analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives, if any, referred to in this research.

The views attributed to third party presenters at Goldman Sachs arranged conferences, including individuals from other parts of Goldman Sachs, do not necessarily reflect those of Global Investment Research and are not an official view of Goldman Sachs.

Any third party referenced herein, including any salespeople, traders and other professionals or members of their household, may have positions in the products mentioned that are inconsistent with the views expressed by analysts named in this report.

This research is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any advice or recommendation in this research is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of investments referred to in this research and the income from them may fluctuate. Past performance is not a guide to future performance, future returns are not guaranteed, and a loss of original capital may occur. Fluctuations in exchange rates could have adverse effects on the value or price of, or income derived from, certain investments.

Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Investors should review current options and futures disclosure documents which are available from Goldman Sachs sales representatives or at <a href="https://www.theocc.com/about/publications/character-risks.jsp">https://www.theocc.com/about/publications/character-risks.jsp</a> and

<u>https://www.fiadocumentation.org/fia/regulatory-disclosures\_1/fia-uniform-futures-and-options-on-futures-risk-disclosures-booklet-pdf-version-2018</u>. Transaction costs may be significant in option strategies calling for multiple purchase and sales of options such as spreads. Supporting documentation will be supplied upon request.

**Differing Levels of Service provided by Global Investment Research:** The level and types of services provided to you by the Global Investment Research division of GS may vary as compared to that provided to internal and other external clients of GS, depending on various factors including your individual preferences as to the frequency and manner of receiving communication, your risk profile and investment focus and perspective (e.g., marketwide, sector specific, long term, short term), the size and scope of your overall client relationship with GS, and legal and regulatory constraints. As an example, certain clients may request to receive notifications when research on specific securities is published, and certain clients may request that specific data underlying analysts' fundamental analysis available on our internal client websites be delivered to them electronically through data feeds or otherwise. No change to an analyst's fundamental research views (e.g., ratings, price targets, or material changes to earnings estimates for equity securities), will be communicated to any client prior to inclusion of such information in a research report broadly disseminated through electronic publication to our internal client websites or through other means, as necessary, to all clients who are entitled to receive such reports.

All research reports are disseminated and available to all clients simultaneously through electronic publication to our internal client websites. Not all research content is redistributed to our clients or available to third-party aggregators, nor is Goldman Sachs responsible for the redistribution of our research by third party aggregators. For research, models or other data related to one or more securities, markets or asset classes (including related services) that may be available to you, please contact your GS representative or go to <a href="https://research.gs.com">https://research.gs.com</a>.

Disclosure information is also available at https://www.gs.com/research/hedge.html or from Research Compliance, 200 West Street, New York, NY 10282.

#### © 2022 Goldman Sachs.

No part of this material may be (i) copied, photocopied or duplicated in any form by any means or (ii) redistributed without the prior written consent of The Goldman Sachs Group, Inc.